Breast Cancer Collaborations Group

The group encompasses all of the Breast Cancer Research positions embedded within other groups across the ICR. These roles enable connectivity between Divisions and bring together expertise across the ICR to drive forwards progress in breast cancer research.

Related news and discoveries

Left: Plates showing the impact of olaparib on BRCA cancer cells and minimal impact of on healthy cells. (Right) Lynparza, olaparib's brand name, drug packaging. Photo credit: Science Museum Group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
See full story